Thereby, the breast tumor markers CEA and CA 15-3 showed good performances for differential diagnosis of breast cancer from healthy women and slightly lower sensitivities when patients with benign breast diseases were used as control groups. This evidence concerns the gene CEACAM5 and breast fibrocystic disease.